Eosinophil-cationic Protein - a Novel Liquid Prognostic Biomarker in Melanoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Mar 9

PMID 30845981

Citations 12

Authors

Annika Kruckel

Alvaro Moreira

Waltraud Frohlich

Gerold Schuler

Lucie Heinzerling

Affiliations

Soon will be listed here.

Abstract

Background: The role of eosinophils in cancer is not yet completely understood, but patients with eosinophilia show a trend towards longer survival in several types of cancer, including melanoma. However, eosinophil count at initial diagnosis of metastatic melanoma does not predict survival. Since eosinophil cationic protein (ECP) mediates anticancer effects, such as tissue remodelling and cytotoxic activity, we investigated this marker as an early prognostic marker in metastatic melanoma.

Methods: Serum of 56 melanoma patients was collected at the time of diagnosis of metastatic disease. ECP levels as measured by ELISA were correlated with overall survival (OS) in patients before systemic therapy with immunotherapy or chemotherapy. Statistical analyses were performed using the Log-Rank (Mantel-Cox) test.

Results: The median OS for patients with high serum ECP above 12.2 ng/ml was 12 months (n = 39), compared to 28 months for patients with ECP below this threshold (n = 17; p = 0.0642). In patients with cutaneous melanoma, excluding patients with uveal and mucosal melanoma, the survival difference was even more striking (p = 0.0393). ECP's effect size on OS was observed independently of the consecutive therapy. ECP levels were not correlated with LDH levels.

Conclusion: ECP seems to be a novel prognostic serum marker for the outcome of melanoma patients, which is independent of LDH and easy to perform in clinical practice. The striking negative prognostic value of high ECP level is unanticipated and can guide patient management.

Citing Articles

Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma.

Brand C, Hunger R, Seyed Jafari S Front Oncol. 2024; 14:1366081.

PMID: 38756652 PMC: 11096470. DOI: 10.3389/fonc.2024.1366081.

Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy.

Guerrero-Juarez C, Goyal P, Amber K Br J Dermatol. 2023; 190(1):137-138.

PMID: 37703325 PMC: 10733625. DOI: 10.1093/bjd/ljad324.

Cationic proteins from eosinophils bind bone morphogenetic protein receptors promoting vascular calcification and atherogenesis.

Meng Z, Zhang S, Li W, Wang Y, Wang M, Liu X Eur Heart J. 2023; 44(29):2763-2783.

PMID: 37279475 PMC: 10393071. DOI: 10.1093/eurheartj/ehad262.

A Proposed New Model to Explain the Role of Low Dose Non-DNA Targeted Radiation Exposure in Chronic Fatigue and Immune Dysfunction Syndrome.

Cocchetto A, Seymour C, Mothersill C Int J Mol Sci. 2023; 24(7).

PMID: 37046994 PMC: 10094351. DOI: 10.3390/ijms24076022.

Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma.

Ammann N, Schwietzer Y, Mess C, Stadler J, Geidel G, Kott J Cancers (Basel). 2022; 14(22).

PMID: 36428768 PMC: 9688620. DOI: 10.3390/cancers14225676.

References

Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C . Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy. 1999; 29(9):1172-86. DOI: 10.1046/j.1365-2222.1999.00542.x. View

von Wasielewski R, Seth S, Franklin J, Fischer R, Hubner K, Hansmann M . Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood. 2000; 95(4):1207-13. View

Molin D, Glimelius B, Sundstrom C, Venge P, Enblad G . The serum levels of eosinophil cationic protein (ECP) are related to the infiltration of eosinophils in the tumours of patients with Hodgkin's disease. Leuk Lymphoma. 2001; 42(3):457-65. DOI: 10.3109/10428190109064602. View

Li N, Mangini J, Bhawan J . New prognostic factors of cutaneous melanoma: a review of the literature. J Cutan Pathol. 2002; 29(6):324-40. DOI: 10.1034/j.1600-0560.2002.290602.x. View

Utikal J, Schadendorf D, Ugurel S . Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res. 2007; 298(10):469-77. PMC: 1800369. DOI: 10.1007/s00403-006-0726-5. View

PETERSON C, ENANDER I, Nystrand J, Anderson A, Nilsson L, Venge P . Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo. Clin Exp Allergy. 1991; 21(5):561-7. DOI: 10.1111/j.1365-2222.1991.tb00847.x. View

Navarro S, Aleu J, Jimenez M, Boix E, Cuchillo C, Nogues M . The cytotoxicity of eosinophil cationic protein/ribonuclease 3 on eukaryotic cell lines takes place through its aggregation on the cell membrane. Cell Mol Life Sci. 2007; 65(2):324-37. PMC: 11131711. DOI: 10.1007/s00018-007-7499-7. View

Murdoch C, Muthana M, Coffelt S, Lewis C . The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008; 8(8):618-31. DOI: 10.1038/nrc2444. View

Boix E, Torrent M, Sanchez D, Nogues M . The antipathogen activities of eosinophil cationic protein. Curr Pharm Biotechnol. 2008; 9(3):141-52. DOI: 10.2174/138920108784567353. View

10.

Legrand F, Driss V, Delbeke M, Loiseau S, Hermann E, Dombrowicz D . Human eosinophils exert TNF-α and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J Immunol. 2010; 185(12):7443-51. DOI: 10.4049/jimmunol.1000446. View

11.

Pereira M, Oliveira D, Kowalski L . The role of eosinophils and eosinophil cationic protein in oral cancer: a review. Arch Oral Biol. 2010; 56(4):353-8. DOI: 10.1016/j.archoralbio.2010.10.015. View

12.

Glimelius I, Rubin J, Fischer M, Molin D, Amini R, Venge P . Effect of eosinophil cationic protein (ECP) on Hodgkin lymphoma cell lines. Exp Hematol. 2011; 39(8):850-8. DOI: 10.1016/j.exphem.2011.05.006. View

13.

Liu Y, Tsai P, Wang Y, Fan T, Hsieh C, Chang M . Chemoattraction of macrophages by secretory molecules derived from cells expressing the signal peptide of eosinophil cationic protein. BMC Syst Biol. 2012; 6:105. PMC: 3478170. DOI: 10.1186/1752-0509-6-105. View

14.

Henry L, Fabre C, Guiraud I, Bastide S, Fabbro-Peray P, Martinez J . Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein. Int J Cancer. 2012; 133(1):142-8. DOI: 10.1002/ijc.27991. View

15.

Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N . Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013; 24(6):1697-703. DOI: 10.1093/annonc/mdt027. View

16.

Davis B, Rothenberg M . Eosinophils and cancer. Cancer Immunol Res. 2014; 2(1):1-8. DOI: 10.1158/2326-6066.CIR-13-0196. View

17.

Zhang Y, Ren H, Wang L, Ning Z, Zhuang Y, Gan J . Clinical impact of tumor-infiltrating inflammatory cells in primary small cell esophageal carcinoma. Int J Mol Sci. 2014; 15(6):9718-34. PMC: 4100116. DOI: 10.3390/ijms15069718. View

18.

Lima P, dos Santos F, Oliveira D, Figueiredo R, Pereira M . Effect of eosinophil cationic protein on human oral squamous carcinoma cell viability. Mol Clin Oncol. 2015; 3(2):353-356. PMC: 4360739. DOI: 10.3892/mco.2014.477. View

19.

Carretero R, Sektioglu I, Garbi N, Salgado O, Beckhove P, Hammerling G . Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015; 16(6):609-17. DOI: 10.1038/ni.3159. View

20.

Sakkal S, Miller S, Apostolopoulos V, Nurgali K . Eosinophils in Cancer: Favourable or Unfavourable?. Curr Med Chem. 2016; 23(7):650-66. DOI: 10.2174/0929867323666160119094313. View